TY - JOUR
T1 - Annual report of the Japanese Breast Cancer Registry for 2017
AU - Hayashi, Naoki
AU - Kumamaru, Hiraku
AU - Isozumi, Urara
AU - Aogi, Kenjiro
AU - Asaga, Sota
AU - Iijima, Kotaro
AU - Kadoya, Takayuki
AU - Kojima, Yasuyuki
AU - Kubo, Makoto
AU - Miyashita, Minoru
AU - Miyata, Hiroaki
AU - Nagahashi, Masayuki
AU - Niikura, Naoki
AU - Ogo, Etsuyo
AU - Tamura, Kenji
AU - Tanakura, Kenta
AU - Yamamoto, Yutaka
AU - Yoshida, Masayuki
AU - Imoto, Shigeru
AU - Jinno, Hiromitsu
N1 - Funding Information:
NH, MK, MM, YK, NN, and YY have received honorariums as a speaker or consultant/advisory role. NN and YY have received grants from Chugai Pharmaceutical Co. MM, YK. YY has received honorariums as a speaker or consultant/advisory role. YY have received grants from Eli Lilly. MM, YK, NN, and YY have received honorariums as a speaker or consultant/advisory role. YY have received grants from Eisai. NH, MM, YK, NN, and YY have received honorariums as a speaker or consultant/advisory role from AstraZeneca. NH, MM, YK, NN, YY, and HK have received honorariums as a speaker or consultant/advisory role. YY have received grants from Pfizer Japan Inc. MM, YK, and YY have received honorariums as a speaker or consultant/advisory role. YY have received grants from Taiho Pharma. MM, YK, and YY have received honorariums as a speaker or consultant/advisory role. YY has received grants from Daiichi-Sankyo. NH, YK, NN, and YY have received honorariums as a speaker or consultant/advisory role. YY have received grants from Novartis Pharma. NH, YK, and YY have received honorariums as a speaker or consultant/advisory role. YY has received grants, and MM has received non-financial support from Kyowa Hakko Kirin. YY has received grants and honorariums as a speaker or consultant/advisory role from Takeda. YY has received grants and honorariums as a speaker or consultant/advisory role from Sysmex. YY has received honorariums as a speaker or consultant/advisory role from GE Health Care Japan. NN has received grants from Nippon Mediphysics, Daiichi-Sankyo, BMS, and MSD. YY has received grants and honorariums as a speaker or consultant/advisory role from Nihon Kayaku. HK has received honorariums as a speaker or consultant/advisory role from Mitsubishi Tanabe Pharma. NH has received honorariums as a speaker or consultant/advisory role from Genomic Health Inc., Devicor Japan, and Allergan Japan. HK, HM, and UI report affiliation with the Department of Healthcare Quality Assessment at the University of Tokyo. The department is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., and the Nipro Corporation. YY and HJ are board members of the Japanese Breast Cancer Society. All of these declarations are outside the submitted work. The other authors declare that they have no conflict of interest.
Funding Information:
The authors thank all the affiliated institutes participating in the Breast Cancer Registry of the JBCS for their efforts to register the patients? data.
Funding Information:
This work was funded by the Registration Committee of the Japanese Breast Cancer Society. Acknowledgements
Publisher Copyright:
© 2020, The Japanese Breast Cancer Society.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: The Japanese Breast Cancer Society Registry started in 1975; it was transferred to the registry platform of the National Clinical Database in 2012. We provide the annual data and an analysis of the Breast Cancer Registry for 2017. Methods: Patients’ characteristics and pathological data of the 95,203 registered Japanese breast cancer patients from 1,427 institutes in 2017 were obtained. Trends in age at diagnosis and pathological stage were determined during the most recent 6 years (2012–2017). Results: The mean onset age was 60.2 years with bimodal peaks at 45–49 years and 65–69 years. A short-term trend of the most recent 6 years of data caused the second, older peak. At diagnosis, 32.4% of breast cancer patients were premenopausal. The distribution of stages revealed that the proportion of early stage breast cancer (stage 0–I) increased up to 60%. At the initial diagnosis, 2.2% of patients presented with metastatic disease. Sentinel node biopsy without axillary node dissection was performed without neoadjuvant chemotherapy (NAC) in 68.8%, and with NAC in 31.1%, of patients. For patients without NAC, lymph node metastasis was less than 3% if the tumor size was less than 1 cm. The proportion of node-negativity decreased to 79.5% when tumor size was 2.1–5 cm. Conclusions: This analysis of the registry provides new information for effective treatment in clinical practice, cancer prevention, and the conduct of clinical trials. Further development of the registry and progress in collecting prognostic data will greatly enhance its scientific value.
AB - Background: The Japanese Breast Cancer Society Registry started in 1975; it was transferred to the registry platform of the National Clinical Database in 2012. We provide the annual data and an analysis of the Breast Cancer Registry for 2017. Methods: Patients’ characteristics and pathological data of the 95,203 registered Japanese breast cancer patients from 1,427 institutes in 2017 were obtained. Trends in age at diagnosis and pathological stage were determined during the most recent 6 years (2012–2017). Results: The mean onset age was 60.2 years with bimodal peaks at 45–49 years and 65–69 years. A short-term trend of the most recent 6 years of data caused the second, older peak. At diagnosis, 32.4% of breast cancer patients were premenopausal. The distribution of stages revealed that the proportion of early stage breast cancer (stage 0–I) increased up to 60%. At the initial diagnosis, 2.2% of patients presented with metastatic disease. Sentinel node biopsy without axillary node dissection was performed without neoadjuvant chemotherapy (NAC) in 68.8%, and with NAC in 31.1%, of patients. For patients without NAC, lymph node metastasis was less than 3% if the tumor size was less than 1 cm. The proportion of node-negativity decreased to 79.5% when tumor size was 2.1–5 cm. Conclusions: This analysis of the registry provides new information for effective treatment in clinical practice, cancer prevention, and the conduct of clinical trials. Further development of the registry and progress in collecting prognostic data will greatly enhance its scientific value.
UR - http://www.scopus.com/inward/record.url?scp=85088583149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088583149&partnerID=8YFLogxK
U2 - 10.1007/s12282-020-01139-3
DO - 10.1007/s12282-020-01139-3
M3 - Article
C2 - 32710374
AN - SCOPUS:85088583149
SN - 1340-6868
VL - 27
SP - 803
EP - 809
JO - Breast Cancer
JF - Breast Cancer
IS - 5
ER -